[8-K] Wave Life Sciences Ltd. Reports Material Event

Rhea-AI Filing Summary

Wave Life Sciences Ltd. furnished an updated corporate presentation for the investment community. The new presentation, dated November 17, 2025, provides business updates and is available in the Investors section of the company’s website. It is also included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.

7 Straits View #12-00 false 0001631574 0001631574 2025-11-17 2025-11-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 7.01 Regulation FD Disclosure.

From time to time, Wave Life Sciences Ltd. (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On November 17, 2025, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 is furnished and not filed:

Exhibit No.		Description
99.1		Corporate Presentation of Wave Life Sciences Ltd. dated November 17, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer

Date: November 17, 2025

FAQ

What did Wave Life Sciences Ltd. (WVE) announce in this 8-K?

Wave Life Sciences Ltd. reported that it updated its corporate presentation for the investment community on November 17, 2025, and made it available on its Investors website and as Exhibit 99.1.

Where can investors find Wave Life Sciences' updated November 17, 2025 corporate presentation?

The updated corporate presentation is available on the Investors section of Wave Life Sciences’ website at http://ir.wavelifesciences.com/ and is furnished as Exhibit 99.1.

How is the new Wave Life Sciences (WVE) presentation treated under SEC rules?

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to its liabilities.

Is the Wave Life Sciences Exhibit 99.1 automatically incorporated into other SEC filings?

No. The presentation in Exhibit 99.1 is not deemed incorporated by reference into any registration statement or other filing unless a future filing expressly incorporates it by specific reference.

Who signed the Wave Life Sciences November 17, 2025 8-K?

The report was signed on behalf of Wave Life Sciences Ltd. by Kyle Moran, the company’s Chief Financial Officer, dated November 17, 2025.

What exhibits were included with this Wave Life Sciences (WVE) 8-K?

The 8-K includes Exhibit 99.1, the corporate presentation dated November 17, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.